Disease Info Card

Uterine Corpus Intravenous Leiomyomatosis

Information about Uterine Corpus Intravenous Leiomyomatosis: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Uterine Corpus Intravenous Leiomyomatosis

Most recent studies have shown that Uterine Corpus Intravenous Leiomyomatosis shares some biological mechanisms with benign-neoplasm, endometrial-stromal-sarcoma, fibroid-tumor, heart-neoplasm, leiomyomatosis, leiomyosarcoma, malignant-paraganglionic-neoplasm, myoma, myomatous-neoplasm, neoplasm-invasiveness, neoplasm-metastasis, neoplasm-recurrence-local, neoplasms, sarcoma, smooth-muscle-tumor, syncope, uterine-fibroids, uterine-neoplasms, vascular-diseases, vascular-neoplasms.

Among the many pathways, these few ones have gauged particular interests from scientists studying Uterine Corpus Intravenous Leiomyomatosis, and have been seen in publications frequently: Angiogenesis, Menopause, Menstruation, Mitosis, Pathogenesis

Quite a number of genes have been found to play important roles in Uterine Corpus Intravenous Leiomyomatosis, such as AMY2A, CD34, CD99, CTLA4, DES, EPB42, ESR1, FGF2, HMGA2, IVL, LCP1, MME, PCNA, PGR, VEGFA, VIM. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.